Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Compellis Pharmaceuticals has announced that its collaborator Pennington Biomedical Research Institute at Louisiana State University has received FDA approval to begin human clinical Phase I obesity studies.
Subscribe to our email newsletter
Enrollment for the program will begin in the first quarter of 2008 with an expected completion date in the second half of the year.
CP404 is a calcium channel blocker used in a nasal formulation to block olfactory activity and alter behavior to reduce food intake. Compellis Pharmaceuticals has tested a series of like compounds and believes the effect can be seen in the overall class of calcium channel blockers. The advantage of CP404 is that it is a small molecule that is well tolerated in man and is readily manufactured.
Christopher Adams, CEO of Compellis, said: “The investigational new drug (IND) application approval is a significant milestone achievement for the Compellis/Pennington obesity therapy development effort. Principal investigator Frank Greenway has significant experience with the clinical development of obesity and nutritional therapies. We are excited about entering the Phase I study and look forward to the clinical results of CP404.”